Amarin Co. plc (NASDAQ:AMRN) – Equities research analysts at Cantor Fitzgerald raised their FY2019 EPS estimates for shares of Amarin in a research note issued to investors on Thursday, May 2nd. Cantor Fitzgerald analyst L. Chen now expects that the biopharmaceutical company will post earnings of ($0.23) per share for the year, up from their previous estimate of ($0.25).

Amarin (NASDAQ:AMRN) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.04. Amarin had a negative net margin of 45.16% and a negative return on equity of 450.07%. The firm had revenue of $73.30 million for the quarter, compared to analysts’ expectations of $67.30 million. During the same period in the previous year, the company posted ($0.07) EPS. The company’s quarterly revenue was up 67.0% compared to the same quarter last year.

Other equities analysts have also recently issued reports about the stock. Citigroup lowered their price objective on shares of Amarin to $20.00 in a research report on Tuesday, January 8th. SunTrust Banks reiterated a “buy” rating on shares of Amarin in a research report on Monday, January 7th. HC Wainwright reiterated a “buy” rating and set a $51.00 price objective on shares of Amarin in a research report on Thursday, January 17th. Stifel Nicolaus initiated coverage on shares of Amarin in a research report on Thursday, March 21st. They set a “buy” rating and a $27.00 price objective on the stock. Finally, BidaskClub upgraded shares of Amarin from a “hold” rating to a “buy” rating in a research report on Wednesday, February 27th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Amarin currently has an average rating of “Buy” and an average price target of $30.43.

NASDAQ AMRN opened at $18.19 on Monday. Amarin has a twelve month low of $2.35 and a twelve month high of $23.33. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.04 and a current ratio of 2.20. The company has a market cap of $5.86 billion, a price-to-earnings ratio of -46.64 and a beta of 1.15.

Large investors have recently modified their holdings of the business. Bank of New York Mellon Corp acquired a new stake in Amarin during the third quarter worth $631,000. BlackRock Inc. increased its stake in Amarin by 0.3% during the third quarter. BlackRock Inc. now owns 3,403,454 shares of the biopharmaceutical company’s stock worth $55,374,000 after acquiring an additional 11,024 shares during the last quarter. Credit Suisse AG acquired a new stake in Amarin during the third quarter worth $198,000. Clearbridge Investments LLC increased its stake in Amarin by 704,126.6% during the third quarter. Clearbridge Investments LLC now owns 3,704,232 shares of the biopharmaceutical company’s stock worth $60,268,000 after acquiring an additional 3,703,706 shares during the last quarter. Finally, Ogorek Anthony Joseph NY ADV acquired a new stake in Amarin during the fourth quarter worth $166,000. 48.47% of the stock is owned by institutional investors.

In other Amarin news, insider Steven B. Ketchum sold 55,543 shares of Amarin stock in a transaction on Friday, March 1st. The shares were sold at an average price of $21.85, for a total transaction of $1,213,614.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Michael Wayne Kalb sold 25,000 shares of Amarin stock in a transaction on Friday, February 15th. The shares were sold at an average price of $17.58, for a total transaction of $439,500.00. The disclosure for this sale can be found here. Insiders have sold a total of 907,136 shares of company stock valued at $18,825,115 in the last three months. Company insiders own 4.08% of the company’s stock.

Amarin Company Profile

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Featured Story: How the Consumer Price Index (CPI) is calculated?

Earnings History and Estimates for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.